NRAS and acute myeloid leukemia: Given that NRAS mutations are commonly found in patients whose AML is resistant to kinase inhibitors (8), and the demonstration that high level expression of NRASG12C in MOLM-14 cells yielded resistance to TUS, it seems likely that this mutation also mediates resistance.